1308256-94-1

Basic information

• Product Name: LHW090-A7
• Synonyms: LHW090-A7;(S)-3-(3'-Chloro-[1,1'-biphenyl]-4-yl)-2-(((S)-1-ethoxy-1-oxopropan-2-yl)amino)propanoic acid;Sodium (2S)-3-(3'-chloro-[1,1'-biphenyl]-4-yl)-2-{[(2S)-1-ethoxy-1-oxopropan-2-yl]amino}propanoate;(alphaS)-3'-Chloro-alpha-[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino][1,1'-biphenyl]-4-propanoic acid;EOS-61103
• CAS NO: 1308256-94-1
• Molecular Formula: C₂₀H₂₂ClNO₄
• Molecular Weight: 375.84598
• EINECS: -0
• Mol File: 1308256-94-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: LHW090-A7(CAS DataBase Reference)
• NIST Chemistry Reference: LHW090-A7(1308256-94-1)
• EPA Substance Registry System: LHW090-A7(1308256-94-1)

Safety Data

• Hazardous Substances Data: 1308256-94-1(Hazardous Substances Data)

Usage

Description

LHW090-A7 is a compound developed as an inhibitor of neutral endopeptidase (NEP), an enzyme responsible for the metabolic inactivation of enkephalins. Inhibitors of NEP have been shown to increase plasma levels of endogenous atrial natriuretic peptides and, as such, are expected to induce natriuretic and diuretic effects.

Upstream product

• 1308432-46-3 (S)-2-amino-3-(3'-chlorobiphenyl-4yl)propionic acid benzyl ester 
• 1308257-52-4 (S)-3-(3'-chlorobiphenyl-4-yl)-2-((S)-1-(ethoxycarbonylethyl)amino)propionic acid benzyl ester 
• 63503-60-6 3-chlorophenylboronic acid 
• 62129-39-9 4-bromo-N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-phenylalanine 
• 1282042-79-8 (S)-2-(tert-butoxycarbonyl)amino-3-(3'-chlorobiphenyl-4-yl)propionic acid 
• 1308257-51-3 (S)-2-amino-3-(3'-chloro-biphenyl-4-yl)-propionic acid benzyl ester hydrochloride 

Downstream Products

• 1308256-93-0 (S)-2-[(S)-2-(3'-chloro-biphenyl-4-yl)-1-(1H-tetrazol-5-ylcarbamoyl)ethylamino]propionic acid ethyl ester 
• 1308257-14-8 (S)-2-{(S)-2-(3'-chlorobiphenyl-4-yl)-1-[methyl-(1H-tetrazol-5-yl)carbamoyl]ethylamino}propionic acid ethyl ester 

Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors

The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.